Asian Journal Of Social Pharmacy

Abstract: Objective To evaluate the economy of domestic bivalent human papilloma virus (HPV) vaccine, imported 9-valent HPV vaccine and 5 cervical cancer screening programs, and to provide a reference for relevant decision-making. Methods A Markov model of the natural disease development of cervical cancer was constructed to simulate the cumulative long-term cost and quality-adjusted life years (QALYs) of one hundred thousand healthy women after they received different interventions for cost-effectiveness analysis. Results and Conclusion Compared with the non-intervention group, the cost of per QALY obtained by two HPV vaccines and 5 screening programs ranged from 1 117.56 yuan to 71 660.48 yuan. Taking China’s GDP per capita in 2020 as the threshold, two HPV vaccines and 5 screening programs are cost-effective. Domestic bivalent vaccine is cost-effective and it should be introduced to the national immunization program in the future. Different screening programs are all cost-effective, too. Among them, careHPV test once every 5 years has the lowest ICER value and it can be used as the first choice for cervical cancer screening in rural areas or resource-limited areas in China.

Key words: